These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 23384720)

  • 1. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes.
    Fujisawa K; Katakami N; Kaneto H; Naka T; Takahara M; Sakamoto F; Irie Y; Miyashita K; Kubo F; Yasuda T; Matsuoka TA; Shimomura I
    Atherosclerosis; 2013 Apr; 227(2):425-8. PubMed ID: 23384720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease.
    Reichert S; Triebert U; Santos AN; Hofmann B; Schaller HG; Schlitt A; Schulz S
    Atherosclerosis; 2017 Nov; 266():234-239. PubMed ID: 28864204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
    Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ
    Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population.
    Norata GD; Garlaschelli K; Grigore L; Tibolla G; Raselli S; Redaelli L; Buccianti G; Catapano AL
    Nutr Metab Cardiovasc Dis; 2009 Feb; 19(2):129-34. PubMed ID: 18595673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity.
    Brix JM; Höllerl F; Kopp HP; Schernthaner GH; Schernthaner G
    Int J Obes (Lond); 2012 Nov; 36(11):1412-7. PubMed ID: 22828946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between a low ankle brachial index and all-cause death and cardiovascular events in subjects with and without diabetes.
    Yokoyama H; Sone H; Honjo J; Okizaki S; Yamada D; Shudo R; Shimizu H; Moriya T; Haneda M
    J Atheroscler Thromb; 2014; 21(6):574-81. PubMed ID: 24492523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes.
    Afarideh M; Aryan Z; Ghajar A; Noshad S; Nakhjavani M; Baber U; Mechanick JI; Esteghamati A
    Atherosclerosis; 2016 Nov; 254():42-51. PubMed ID: 27684605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Imaizumi T
    Mol Med; 2007; 13(3-4):185-9. PubMed ID: 17592553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
    Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
    Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients.
    Yan XX; Lu L; Peng WH; Wang LJ; Zhang Q; Zhang RY; Chen QJ; Shen WF
    Atherosclerosis; 2009 Aug; 205(2):544-8. PubMed ID: 19150066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus.
    Brownrigg JR; de Lusignan S; McGovern A; Hughes C; Thompson MM; Ray KK; Hinchliffe RJ
    Heart; 2014 Dec; 100(23):1837-43. PubMed ID: 25095826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
    Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-sRAGE autoimmunity in obesity: downturn after bariatric surgery is independent of previous diabetic status.
    Lorenzi R; Pattou F; Beuscart JB; Grossin N; Lambert M; Fontaine P; Caiazzo R; Pigeyre M; Patrice A; Daroux M; Boulanger E; Dubucquoi S
    Diabetes Metab; 2014 Nov; 40(5):356-62. PubMed ID: 24933232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score.
    Raposeiras-Roubín S; Rodiño-Janeiro BK; Grigorian-Shamagian L; Moure-González M; Seoane-Blanco A; Varela-Román A; Almenar-Bonet L; Alvarez E; González-Juanatey JR
    Am J Cardiol; 2011 Mar; 107(6):938-44. PubMed ID: 21247530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
    Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.